A Case Report on Pityriasis Rubra Pilaris (PRP) and Multisystem Inflammatory Syndrome in Children (MIS-C)

Abstract

Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease of unknown etiology. There are six distinct types of PRP. A higher incidence was reported within the pediatric group, but treatment remains largely empiric, based on case reports and series. The condition is often refractory to treatment, especially initially, with topical corticosteroids and oral Acitretin the more commonly employed agents. biologic agents approved for psoriasis have been used with good effect in PRP. Multisystem Inflammatory Syndrome in Children (MIS-C) is a new disease entity that evolved as a result of the coronavirus disease 2019 (COVID-19) pandemic. Due to our incomplete understanding of the occurrence of MISC, new diagnostic and therapeutic issues have emerged. The American college of rheumatology (ACR) has recommended the use of intravenous immunoglobulin (IV IG) and/or high-dose corticosteroids as first-line treatment in these patients. In some cases of severe patients may receive such as a second dose of IV IG, Anakinra or Infliximab and Aspirin. Here we report the case of a 4-year-old boy presented with rashes. We describe the successful use of IV IG, corticosteroids, and Aspirin for treatment of MIS-C and PRP. Keywords: Pityriasis rubra pilaris, MIS-C, IV IG